Simplification and first validation of a short battery of patient questionnaires for clinical management of HIV-infected patients: The HIV-SQUAD (symptom quality of life adherence) questionnaire®

HIV Clinical Trials

Volumn 10, Issue 4, 2009, Pages 215-232

  Spire, B ^a   Arnould, B ^b   Barbier, F ^c   Durant, J ^d   Gilquin, J ^e   Landman, R ^f   Carret, S ^g   Saussier, C ^h   El Kebir, S ^h   Cohen Codar, I ^g  

^a INSERM   (France)

^b MAPI VALUES   (United States)

^c TRT 5   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e SAINT JOSEPH HOSPITAL   (France)

^f BICHAT HOSPITAL   (France)

^g Abbott   (France)

^h MAPI SA   (France)

Author keywords

Adherence; HIV infection; HRQoL; Patient reported outcomes (PRO); Self administered questionnaire; Tolerability

Indexed keywords

LOPINAVIR PLUS RITONAVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; DISCRIMINANT VALIDITY; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HIV SYMPTOM QUALITY OF LIFE ADHERENCE QUESTIONNAIRE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSTRUMENT VALIDATION; INTERNAL CONSISTENCY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; PSYCHOMETRY; QUALITY OF LIFE; STRUCTURED QUESTIONNAIRE; VIRUS DIAGNOSIS; VIRUS LOAD; VISUAL ANALOG SCALE; WELLBEING;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 70349144903     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1004-215     Document Type: Article

References (52)

1. Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ ritonavir). Ann Pharmacother. 2002;36:1193 1203.
2. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63:769-802.
3. Voigt E, Wasmuth JC, Vogel M, et al. Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results. Infection. 2004;32:82-88.
4. Bader A, Kremer H, Erlich-Trungenberger I, et al. An adherence typology: coping, quality of life, and physical symptoms of people living with HIV/AIDS and their adherence to antiretroviral treatment. Med Sci Monit. 2006;12: CR493-CR500.
5. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2:38-45.
6. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124-133.
7. Marquis P, Arnould B, Acquadro C, Roberts W.M. Patientreported outcomes and health-related quality of life in effectiveness studies: pros and cons. Drug Develop Res. 2006;67:193-201.
8. Patrick DL, Burke LB, Powers JH, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health. 2007;10 (Suppl 2): S125 137.
9. Pharmacoeconomics 2001, 1, 187-195.
10. Apolone G, De CG, Brunetti M, Garattini S. Healthrelated quality of life (HR-QOL) and regulatory issues. An assessment of the European agency for the evaluation of medicinal products (EMEA) recommendations on the use of HR-QOL measures in drug approval. Pharmacoeconomics. 2001;19:187-195.
11. European Medicines Agency. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. Available at: http://www.emea.europa.eu/ pdfs/human/ewp/13939104en.pdf. Accessed July 8, 2009.
12. Spilker B, Molinek Jr FR, Johnston KA, Simpson RL Jr, Tilson HH. Quality of life bibliography and indexes. Med Care. 1990;28:DS1-77.
13. Deyo RA. The quality of life, research, and care. Ann Intern Med. 1991;114:695-697.
14. Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegelhalter D, Cox D. Quality of life measures in health care. I: Applications and issues in assessment. BMJ. 1992;305: 1074-1077.
15. Jia H, Uphold CR, Wu S, Chen GJ, Duncan PW. Predictors of changes in health-related quality of life among men with HIV infection in the HAART era. AIDS Patient Care STDS. 2005;19:395-405.
16. Lorenz KA, Cunningham WE, Spritzer KL, Hays RD. Changes in symptoms and health-related quality of life in a nationally representative sample of adults in treatment for HIV. Qual Life Res. 2006;15:951-958.
17. Jia H, Uphold CR, Zheng Y, et al. A further investigation of health-related quality of life over time among men with HIV infection in the HAART era. Qual Life Res. 2007;16:961-968.
18. Carballo E, Cadarso-Suarez C, Carrera I, et al. Assessing relationships between health-related quality of life and adherence to antiretroviral therapy. Qual Life Res. 2004;13:587-599.
19. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med. 2002;54:1481-1496.
20. Carrieri P, Raffi F, Lewden C, et al, and the APROCO study group. Impact of early versus late adherence to highly active antiretroviral therapy on immuno- virological response: a 3 year follow-up study. Antiviral Ther. 2003;8:37-46.
21. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defi c Syndr. 2001;28: 445-449.
22. Foster JM, van der MT, Caeser M, Hannaford P. The use of questionnaires for measuring patient-reported side effects of drugs: its importance and methodological challenges. Pharmacoepidemiol Drug Saf. 2008;17:278-296.
23. Tobias CR, Cunningham W, Cabral HD, et al. Living with HIV but without medical care: barriers to engagement. AIDS Patient Care STDS. 2007;21(6):426-434.
24. Hsiung PC, Fang CT, Chang YY, Chen MY, Wang JD. Comparison of WHOQOL-BREF and SF-36 in patients with HIV infection. Qual Life Res. 2005;14(1):141-150.
25. Mrus JM, Sherman KE, Leonard AC, Sherman SN, Mandell KL, Tsevat J. Health values of patients coinfected with HIV/ hepatitis C: are two viruses worse than one? Med Care. 2006;44(2):158-166.
26. World Health Organization. World Health Organization Quality of Life-BREF (WHOQOL-BREF). Available at: http://www.who.int/substance-abuse/research-tools/ whoqolbref/en/. Accessed July 8, 2009.
27. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care. 1991;29:786-798.
28. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6:481-493.
29. Cella D.F, McCain N.L, Peterman A.H, Mo F, Wolen D. Development and validation of the Functional Assessment of Human Immunodefi ciency Virus Infection (FAHI) quality of life instrument. Qual Life Res. 1996;5:450-463.
30. Peterman AH, Cella D, Mo F, McCain N. Psychometric validation of the revised Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument. Qual Life Res. 1997;6:572-584.
31. Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(Suppl 1):S77-90.
32. Duracinsky M, Cervoni J, Vincent V, et al. Cultural adaptation and validation of a lipodystrophy specifi c quality of life questionnaire. Int Conf AIDS. 2004:7:11-16.
33. DeMasi RA, Graham NM, Tolson JM, et al. Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome. Adv Ther. 2001;18:163-173.
34. Pratt RJ, Robinson N, Loveday HP, et al. Adherence to antiretroviral therapy: appropriate use of self-reporting in clinical practice. HIV Clin Trials. 2001;2:146-159.
35. Sodergard B, Halvarsson M, Tully MP, et al. Adherence to treatment in Swedish HIV-infected patients. J Clin Pharm Ther. 2006;31:605-616.
36. Mannheimer SB, Mukherjee R, Hirschhorn LR, et al. The CASE adherence index: a novel method for measuring adherence to antiretroviral therapy. AIDS Care. 2006;18:853-861.
37. Spire B, Carrieri P, Sopha P, et al. Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment. Antivir Ther. 2008;13(5):697-703.
38. Duran S, Saves M, Spire B, et al. Failure to maintain longterm adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15:2441-2444.
39. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36:1100-1102.
40. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 2004;5:74-79.
41. Carrieri P, Cailleton V, Le M, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defi c Syndr. 2001;28:232-239.
42. World Health Organization. World Health Organization Quality of Life HIV instrument (WHOQOL-HIV). Users manual. Scoring and coding for the WHOQOL-HIV instruments. Available at: http://www.who.int/mental-health/media/en/613.pdf. Accessed July 8, 2009.
43. Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N. Patient-reported outcomes: the example of health-related-quality of life - a European guidance document for the improved integration of HRQL assessment in the drug regulatory process. Drug Inf. 2002;36: 209-238.
44. Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res. 2000;9:887-900.
45. Santanello NC, Baker D, Cappelleri JC, et al. Regulatory issues for health-related quality of life--PhRMA Health Outcomes Committee workshop, 1999. Value Health. 2002;5:14-25.
46. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality-oflife instruments: attributes and review criteria. Qual Life Res.2002;11:193-205.
47. Carrieri MP, Raffi F, Lewden C, et al, APROCO Study Group. Impact of early versus late adherence to highly active antiretroviral therapy on immuno- virological response: a 3-year follow-up study. Antivir Ther. 2003;8(6):585-594.
48. Hamon A, Mesbah M. [Internal statistical validation of a quality of life questionnaire]. Rev Epidemiol Sante Publique. 1999;47:571 583.
49. Campbell DT, Fiske DW. Convergent and discriminant validation by the multitrait-multimethod matrix. Psychol Bull. 1959;56:81 105.
50. Cronbach LJ. Coeffi cient alpha and the internal structure of tests. Psychometrika. 1951;16(3):297 334.
51. Nunnally J, Bernstein IH. Psychometric Theory. 3rd ed. New York: McGraw-Hill; 1994.
52. Cohen J. Statistical Powers Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Erlbaum; 1988.